1. Towards a cancer mission in Horizon Europe: recommendations
- Author
-
Kathi Apostolidis, Alexander M.M. Eggermont, Simon Oberst, Hans-Olov Adami, Fabien Calvo, Carlos Caldas, Ulrik Ringborg, Thierry Philip, Nancy Abou-Zeid, Josep Tabernero, Gerd Nettekoven, Francesco De Lorenzo, Neil K. Aaronson, Richard Price, Michael Baumann, Sakari Karjalainen, Emile E. Voest, Miklós Kásler, Frederik Falkenburg, Angelika Eggert, Bengt Jönsson, Douglas Hanahan, Mette Kalager, Péter Nagy, Caroline Dive, Manuel Heitor, Anton Berns, René Bernards, Ulrike Helbig, Eric Solary, Julio E. Celis, Carolina Espina, Klas Kärre, Pamela Kearns, Peter Strang, Françoise Meunier, Joachim Schüz, Alberto Bardelli, Jérôme Foucaud, Denis Lacombe, Yvonne Brandberg, Berns, Anton [0000-0003-2194-1988], Baumann, Michael [0000-0002-9340-974X], Espina, Carolina [0000-0001-6848-4687], Schüz, Joachim [0000-0001-9687-2134], Apollo - University of Cambridge Repository, Institut Català de la Salut, [Berns A] The Netherlands Cancer Institute, Amsterdam, the Netherlands. European Academy of Cancer Sciences, Stockholm, Sweden. [Ringborg U] European Academy of Cancer Sciences, Stockholm, Sweden. Cancer Center Karolinska, Karolinska University Hospital, Stockholm, Sweden. [Celis JE] European Academy of Cancer Sciences, Stockholm, Sweden. Danish Cancer Society Research Centre, Copenhagen, Denmark. [Heitor M] Ministry for Science, Technology and Higher Education, Lisbon, Portugal. [Aaronson NK] The Netherlands Cancer Institute, Amsterdam, the Netherlands. [Abou-Zeid N] Fondation ARC pour la recherche sur le cancer, Villejuif, France. [Tabernero J] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
0301 basic medicine ,Otros calificadores::Otros calificadores::/prevención & control [Otros calificadores] ,Cancer Research ,Process management ,Palliative care ,Biomedical ,Translational Research, Biomedical ,0302 clinical medicine ,Cancer Survivors ,cancer mission ,cancer research/care/prevention continuum ,comprehensive cancer centres ,European healthcare systems ,patient empowerment ,science policy ,Clinical Trials as Topic ,Europe ,Humans ,Neoplasms ,Organizational Innovation ,Palliative Care ,Patient Participation ,Specialization ,media_common ,General Medicine ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Medicina - Investigació ,Oncology ,Natural Science Disciplines::Science::Research::Biomedical Research::Translational Medical Research [DISCIPLINES AND OCCUPATIONS] ,030220 oncology & carcinogenesis ,Molecular Medicine ,Càncer - Prevenció ,disciplinas de las ciencias naturales::ciencia::investigación::investigación biomédica::investigación médica traslacional [DISCIPLINAS Y OCUPACIONES] ,Science policy ,medicine.medical_specialty ,Translational research ,Harmonization ,lcsh:RC254-282 ,neoplasias [ENFERMEDADES] ,Critical mass (sociodynamics) ,Other subheadings::Other subheadings::/prevention & control [Other subheadings] ,03 medical and health sciences ,Translational Research ,Genetics ,medicine ,media_common.cataloged_instance ,European union ,Neoplasms [DISEASES] ,030104 developmental biology ,Policy Article ,Portfolio ,Business ,Outcomes research - Abstract
A comprehensive cancer approach covering the entire research–care–prevention continuum can achieve a 10‐year cancer‐specific survival for 75% of patients diagnosed in EU member states with well‐developed health care by 2030. To ensure access to a critical mass of patient biological and technological resources, infrastructures for translational research, clinical and prevention trials, and outcomes research are needed. Here, we provide recommendations for achieving key targets and prioritize research areas., A comprehensive translational cancer research approach focused on personalized and precision medicine, and covering the entire cancer research–care–prevention continuum has the potential to achieve in 2030 a 10‐year cancer‐specific survival for 75% of patients diagnosed in European Union (EU) member states with a well‐developed healthcare system. Concerted actions across this continuum that spans from basic and preclinical research through clinical and prevention research to outcomes research, along with the establishment of interconnected high‐quality infrastructures for translational research, clinical and prevention trials and outcomes research, will ensure that science‐driven and social innovations benefit patients and individuals at risk across the EU. European infrastructures involving comprehensive cancer centres (CCCs) and CCC‐like entities will provide researchers with access to the required critical mass of patients, biological materials and technological resources and can bridge research with healthcare systems. Here, we prioritize research areas to ensure a balanced research portfolio and provide recommendations for achieving key targets. Meeting these targets will require harmonization of EU and national priorities and policies, improved research coordination at the national, regional and EU level and increasingly efficient and flexible funding mechanisms. Long‐term support by the EU and commitment of Member States to specialized schemes are also needed for the establishment and sustainability of trans‐border infrastructures and networks. In addition to effectively engaging policymakers, all relevant stakeholders within the entire continuum should consensually inform policy through evidence‐based advice.
- Published
- 2020